U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07479108) titled 'Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE(R) (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions' on March 09.
Brief Summary: Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
Study Start Date: Nov. 29, 2024
Study Type: INTERVENTIONAL
Condition:
Bioequivalance
Intervention:
DRUG: Empagliflozin (Jardiance(R))
Reference. empagliflozin 25 mg tablet
DRUG: Empagliflozin (oral)
Test. empagliflozin 25 mg tablet
Recruitment Status: COMPLETED
Sponsor: ADIUM
Published by HT Digital Conten...